# Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma

> **NCT01234766** · PHASE2 · COMPLETED · sponsor: **Dartmouth-Hitchcock Medical Center** · enrollment: 39 (actual)

## Conditions studied

- Lymphoma, Follicular

## Interventions

- **DRUG:** Bendamustine
- **DRUG:** Rituximab
- **RADIATION:** Y-90 ibritumomab

## Key facts

- **NCT ID:** NCT01234766
- **Lead sponsor:** Dartmouth-Hitchcock Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2021-01
- **Final completion:** 2021-04-01
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2021-05-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01234766

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01234766, "Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01234766. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*